Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults.

Laurent PE, Bourhy H, Fantino M, Alchas P, Mikszta JA.

Vaccine. 2010 Aug 16;28(36):5850-6. doi: 10.1016/j.vaccine.2010.06.062. Epub 2010 Jun 30.

PMID:
20600481
2.

Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs.

Harvey AJ, Kaestner SA, Sutter DE, Harvey NG, Mikszta JA, Pettis RJ.

Pharm Res. 2011 Jan;28(1):107-16. doi: 10.1007/s11095-010-0123-9. Epub 2010 Mar 31.

PMID:
20354765
3.

Microneedle-based vaccines.

Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK.

Curr Top Microbiol Immunol. 2009;333:369-93. doi: 10.1007/978-3-540-92165-3_18. Review.

4.

Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine.

Huang J, D'Souza AJ, Alarcon JB, Mikszta JA, Ford BM, Ferriter MS, Evans M, Stewart T, Amemiya K, Ulrich RG, Sullivan VJ.

Clin Vaccine Immunol. 2009 May;16(5):719-25. doi: 10.1128/CVI.00447-08. Epub 2009 Mar 4.

5.

Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook.

Mikszta JA, Laurent PE.

Expert Rev Vaccines. 2008 Nov;7(9):1329-39. doi: 10.1586/14760584.7.9.1329. Review.

PMID:
18980537
6.

An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shock.

Morefield GL, Tammariello RF, Purcell BK, Worsham PL, Chapman J, Smith LA, Alarcon JB, Mikszta JA, Ulrich RG.

J Immune Based Ther Vaccines. 2008 Sep 3;6:5. doi: 10.1186/1476-8518-6-5.

7.

Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system.

Laurent PE, Bonnet S, Alchas P, Regolini P, Mikszta JA, Pettis R, Harvey NG.

Vaccine. 2007 Dec 17;25(52):8833-42. Epub 2007 Oct 29.

PMID:
18023942
8.

Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge.

Huang J, Mikszta JA, Ferriter MS, Jiang G, Harvey NG, Dyas B, Roy CJ, Ulrich RG, Sullivan VJ.

Hum Vaccin. 2007 May-Jun;3(3):90-3. Epub 2007 May 13.

PMID:
17375001
9.

Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines.

Alarcon JB, Hartley AW, Harvey NG, Mikszta JA.

Clin Vaccine Immunol. 2007 Apr;14(4):375-81. Epub 2007 Feb 28.

10.

Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine.

Mikszta JA, Dekker JP 3rd, Harvey NG, Dean CH, Brittingham JM, Huang J, Sullivan VJ, Dyas B, Roy CJ, Ulrich RG.

Infect Immun. 2006 Dec;74(12):6806-10. Epub 2006 Oct 9.

11.

Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates.

Dean CH, Alarcon JB, Waterston AM, Draper K, Early R, Guirakhoo F, Monath TP, Mikszta JA.

Hum Vaccin. 2005 May-Jun;1(3):106-11. Epub 2005 May 9. Erratum in: Hum Vaccin. 2005 Sep-Oct;1(5):179.

PMID:
17012854
12.

Formulation of a dry powder influenza vaccine for nasal delivery.

Garmise RJ, Mar K, Crowder TM, Hwang CR, Ferriter M, Huang J, Mikszta JA, Sullivan VJ, Hickey AJ.

AAPS PharmSciTech. 2006 Mar 10;7(1):E19.

13.

Formulation of a dry powder influenza vaccine for nasal delivery.

Garmise RJ, Mar K, Crowder TM, Hwang CR, Ferriter M, Huang J, Mikszta JA, Sullivan VJ, Hickey AJ.

AAPS PharmSciTech. 2006 Mar;7(1):E131-E137. doi: 10.1208/pt070119. Epub 2017 Mar 8.

14.

Noninvasive delivery technologies: respiratory delivery of vaccines.

Sullivan VJ, Mikszta JA, Laurent P, Huang J, Ford B.

Expert Opin Drug Deliv. 2006 Jan;3(1):87-95. Review.

PMID:
16370942
15.

Anthrax vaccine powder formulations for nasal mucosal delivery.

Jiang G, Joshi SB, Peek LJ, Brandau DT, Huang J, Ferriter MS, Woodley WD, Ford BM, Mar KD, Mikszta JA, Hwang CR, Ulrich R, Harvey NG, Middaugh CR, Sullivan VJ.

J Pharm Sci. 2006 Jan;95(1):80-96.

PMID:
16315230
16.

Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms.

Mikszta JA, Sullivan VJ, Dean C, Waterston AM, Alarcon JB, Dekker JP 3rd, Brittingham JM, Huang J, Hwang CR, Ferriter M, Jiang G, Mar K, Saikh KU, Stiles BG, Roy CJ, Ulrich RG, Harvey NG.

J Infect Dis. 2005 Jan 15;191(2):278-88. Epub 2004 Dec 15.

PMID:
15609239
17.

A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats.

Huang J, Garmise RJ, Crowder TM, Mar K, Hwang CR, Hickey AJ, Mikszta JA, Sullivan VJ.

Vaccine. 2004 Dec 21;23(6):794-801.

PMID:
15542204
18.

Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery.

Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis RJ, Harvey NG.

Nat Med. 2002 Apr;8(4):415-9.

PMID:
11927950
19.

Processing and reactivity of T cell epitopes containing two cysteine residues from hen egg-white lysozyme (HEL74-90).

Kang HK, Mikszta JA, Deng H, Sercarz EE, Jensen PE, Kim BS.

J Immunol. 2000 Feb 15;164(4):1775-82.

20.

Antigen-driven selection of TCR In vivo: related TCR alpha-chains pair with diverse TCR beta-chains.

Mikszta JA, McHeyzer-Williams LJ, McHeyzer-Williams MG.

J Immunol. 1999 Dec 1;163(11):5978-88.

21.
22.
23.
24.

Impaired antigen presentation by splenocytes of ethanol-consuming C57BL/6 mice.

Mikszta JA, Waltenbaugh C, Kim BS.

Alcohol. 1995 May-Jun;12(3):265-71.

PMID:
7543758
25.

Supplemental Content

Loading ...
Support Center